Faculty Profiles - MARUYAMA, Shoichi

Papers - MARUYAMA, Shoichi

Division display 101 - 120 of about 410 ／ All the affair displays >>

Effect of Low-Density Lipoprotein Apheresis on Quality of Life in Patients with Diabetes, Proteinuria, and Hypercholesterolemia Reviewed

Hara, A; Wada, T; Muso, E; Maruyama, S; Kato, S; Furuichi, K; Yoshimura, K; Toyama, T; Sakai, N; Suzuki, H; Tsukamoto, T; Miyazaki, M; Sato, E; Abe, M; Shibagaki, Y; Narita, I; Goto, S; Sakamaki, Y; Yokoyama, H; Mori, N; Tanaka, S; Yuzawa, Y; Hasegawa, M; Matsubara, T; Wada, J; Tanabe, K; Masutani, K; Abe, Y; Tsuruya, K; Fujimoto, S; Iwatsubo, S; Tsuda, A; Suzuki, H; Kasuno, K; Terada, Y; Nakata, T; Iino, N; Sofue, T; Miyata, H; Nakano, T; Ohtake, T; Kobayashi, S

Blood Purif Vol. 52 ( 4 ) page： 373 - 381 2023.4

Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis (a multicenter cohort study) Reviewed Open Access

Shirai, S; Yasuda, T; Kumagai, H; Matsunobu, H; Ichikawa, D; Shibagaki, Y; Yasuda, Y; Matsuzaki, K; Hirano, K; Kawamura, T; Suzuki, Y; Maruyama, S

Clin Exp Nephrol Vol. 27 ( 4 ) page： 340 - 348 2023.4

Long non-coding RNA lnc-CHAF1B-3 promotes renal interstitial fibrosis by regulating EMT-related genes in renal proximal tubular cells Reviewed Open Access

Imai, K; Ishimoto, T; Doke, T; Tsuboi, T; Watanabe, Y; Katsushima, K; Suzuki, M; Oishi, H; Furuhashi, K; Ito, Y; Kondo, Y; Maruyama, S

Mol Ther Nucleic Acids Vol. 31 page： 139 - 150 2023.3

Serum and plasma levels of Ba, but not those of soluble C5b-9, might be affected by renal function in chronic kidney disease patients Reviewed Open Access

Yamane, R; Yasuda, Y; Oshima, A; Suzuki, Y; Kojima, H; Kim, H; Fukui, S; Maruyama, S; Ito, Y; Mizuno, M

BMC Nephrol Vol. 24 ( 1 ) page： 26 2023.2

Non-A Blood Type Is a Risk Factor for Poor Cardio-Cerebrovascular Outcomes in Patients Undergoing Dialysis Reviewed Open Access

Nakayama, T; Yamamoto, J; Ozeki, T; Tsuruta, Y; Yokoi, M; Aoi, T; Mori, Y; Hori, M; Tsujita, M; Shirasawa, Y; Kondo, C; Yasuda, K; Murata, M; Kinoshita, Y; Suzuki, S; Fukuda, M; Yamazaki, C; Ikehara, N; Sugiura, M; Goto, T; Hashimoto, H; Yajima, K; Maruyama, S; Morozumi, K; Seo, Y

Biomedicines Vol. 11 ( 2 ) page： 592 2023.2

Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients Reviewed Open Access

Fujieda, K; Tanaka, A; Kikuchi, R; Takai, N; Saito, S; Yasuda, Y; Fujita, T; Kato, M; Furuhashi, K; Maruyama, S

Vaccines (Basel) Vol. 11 ( 1 ) page： 134 2023.1

腎移植後ガンシクロビル耐性サイトメガロウイルス感染となった2例

佐野優太, 石田昇平, 佐野友康, 加藤真史, 田中章仁, 齋藤尚二, 安田宜成, 丸山彰一, 赤松秀輔

移植 Vol. 58 ( Supplement ) page： s274_2 - s274_2 2023

Language：Japanese Publisher：一般社団法人日本移植学会

サイトメガロウイルス(CMV)感染症は最も頻度が高く重要な移植後ウイルス感染症である。治療にはまずガンシクロビル(GCV)、バルガンシクロビル(VGCV)が使用されるが、今回移植後GCV耐性CMV感染となり、ホスカルネットナトリウムにて治癒した2例を経験したので報告する。症例1:50代男性。X-17年より血液透析導入。Caroli病による頻回の胆管炎で入院を繰り返していた。ドナーは50代女性。原疾患は脳出血。脳死下肝腎同時移植施行。S-Cre1.00mg/dl前後で安定し、特記合併症なく術後約一か月で退院となった。CMV抗体陽性。術後7か月後、CMV感染となりVGCV内服開始。内服開始後もCMV感染の改善見られず、GCV耐性が判明しホスカルネットナトリウム投与開始。特記合併症なく治癒した。症例2:40代男性。X年、悪性高血圧による慢性腎不全にて血液透析導入。母親をドナーとした生体腎移植施行。S-Cre2.00mg/dl前後で安定し、特記合併症なく術後約一か月で退院となった。レシピエントCMV抗体陰性、ドナーCMV抗体陽性であったためVGCV予防内服を開始した。術後6か月後、CMV感染となりVGCV内服を治療量へ増やした。内服開始後もCMV感染の改善見られず、GCV耐性が判明しホスカルネットナトリウム投与開始。特記合併症なく治癒した。今回、移植後GCV耐性CMVに対してホスカルネットナトリムを使用し、特記問題なく治癒した症例を経験したので若干の文献的考察を加えて報告する。

DOI： 10.11386/jst.58.supplement_s274_2

CiNii Research

生体腎移植ドナーにおける腎提供後のフォローアップの重要性

安田宜成, 田中章仁, 齋藤尚二, 加藤規利, 小杉智規, 佐野優太, 加藤真史, 丸山彰一

移植 Vol. 58 ( Supplement ) page： s248_3 - s248_3 2023

Language：Japanese Publisher：一般社団法人日本移植学会

【目的】日本透析医学会の統計調査では慢性維持透析患者107 人（0.043％）が腎移植ドナーとしての腎提供ありと回答した。名古屋大学の生体腎移植ドナーの予後を調査した。【方法】対象は1998年以降に名古屋大学で生体腎移植のため腎提供したドナー167名。内2020～22年に受診した138名の最終診察時のCKD重症度分類を調査した。受診がない29名について背景を調査した。【結果】生体腎移植ドナーのGFR区分はG2:18名（13.0％）、G3a:74名（53.6％）、G3b:44名（31.9％）G4:2名（1.5％）、蛋白尿区分はA1:103名（74.6％）、A2:25名（18.1％）、A3:5名（3.6％）、未測定5名（3.6％）であった。G4の1名は73歳男性で腎提供前の2回の実測Ｃｃｒ平均は126.15ｍＬ/分であったが腎提供後に高血圧を合併し、腎提供後15年以上の経過で大動脈瘤手術を受けていた。残る1名は80歳女性で腎提供前の実測GFRは113.9で、腎提供後も10年以上安定していたが、急性腎障害後に腎機能が低下した。A3の4名では、腎提供前の高血圧合併2名、肥満1名だった。

DOI： 10.11386/jst.58.supplement_s248_3

CiNii Research

Efficacy of On-line Hemodiafiltration for Rhabdomyolysis Presenting with Acute Kidney Injury Due to Unexpected Drug Abuse Open Access

Sato Naokazu, Inagaki Koji, Takanashi Masahiro, Muto Reiko, Kato Noritoshi, Maruyama Shoichi, Akahori Toshiyuki

Internal Medicine Vol. 62 ( 19 ) page： 2865 - 2870 2023

Language：English Publisher：The Japanese Society of Internal Medicine

Myoglobin is a well-known cause of acute kidney injury (AKI) due to rhabdomyolysis. However, whether or not removing serum myoglobin by on-line hemodiafiltration (OHDF) improves the kidney function remains unclear. We herein report a patient with a history of methamphetamine abuse who developed AKI due to rhabdomyolysis. A urinalysis and blood collection results obtained before and after OHDF demonstrated that OHDF improved the kidney function by removing a large amount of serum myoglobin rather than via urinary excretion. In conclusion, OHDF may prevent AKI progression effectively when the urine volume is insufficient.

DOI： 10.2169/internalmedicine.1107-22

Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis Open Access

Muto Reiko, Suzuki Yasuhiro, Shimizu Hideaki, Yasuda Kaoru, Ishimoto Takuji, Maruyama Shoichi, Ito Yasuhiko, Mizuno Masashi

Internal Medicine Vol. 62 ( 3 ) page： 565 - 569 2023

Language：English Publisher：The Japanese Society of Internal Medicine

Fabry disease is an X-linked lysosomal storage disorder due to mutations in the alpha-galactosidase A gene, which leads to the accumulation of globotriaosylceramide in various organs. In Fabry disease with end-stage renal disease (ESRD), cerebrovascular events are lethal, even with enzyme replacement therapy (ERT). However, the utility of biomarkers to evaluate the ERT response is unclear. We herein report a case of recurrent cerebrovascular complications under ERT in a Fabry disease patient, progressing to ESRD on peritoneal dialysis. Further studies are warranted, but Fabry disease patients with ESRD receiving ERT might need careful long-term follow-up in cases with cerebrovascular manifestations.

DOI： 10.2169/internalmedicine.0185-22

The Impact of Liver Chemistries on Respiratory Failure among Hemodialysis Patients with COVID-19 during the Omicron Wave Open Access

Hori Mayuko, Yasuda Kaoru, Takahashi Hiroshi, Aoi Tomonori, Mori Yoshiko, Tsujita Makoto, Shirasawa Yuichi, Kondo Chika, Hashimoto Takashi, Koyama Hiroichi, Morozumi Kunio, Maruyama Shoichi

Internal Medicine Vol. 62 ( 18 ) page： 2617 - 2625 2023

Language：English Publisher：The Japanese Society of Internal Medicine

Objective Although the coronavirus disease 2019 (COVID-19) Omicron variant causes less severe symptoms than previous variants, early indicators for respiratory failure are needed in hemodialysis patients, who have a higher mortality rate than the general population. Liver chemistries are known to reflect the severity of COVID-19 in the general population. This study explored the early indicators for worsened respiratory failure based on patient characteristics, including liver chemistries. Methods This retrospective study included 117 patients admitted for COVID-19 during the Omicron wave. Respiratory failure was defined as oxygen requirement during treatment. Information on the symptoms and clinical characteristics, including liver chemistries [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], at admission was collected. Results Thirty-five patients (29.9%) required oxygen supply during treatment. In the multivariate logistic regression analyses, AST [odds ratio (OR) 1.06, 95% confidence interval (CI) 1.00-1.13, p=0.029], ALT (OR 1.09, 95% CI 1.02-1.18, p=0.009), and moderate COVID-19 illness (Model including AST, OR 6.95, 95% CI 2.23-23.17, p<0.001; Model including ALT, OR 7.19, 95% CI 2.21-25.22, p=0.001) were independent predictors for respiratory failure. Based on the cutoff values determined by the receiver operating characteristic curve, higher AST (≥23 IU/L) and ALT levels (≥14 IU/L) were also independently associated with respiratory failure (higher AST: 64.3% vs. 18.8%, OR 3.44, 95% CI 1.08-11.10, p=0.035; higher ALT: 48.8% vs. 19.7%, OR 4.23, 95% CI 1.34-14.52, p=0.013, respectively). Conclusion The measurement of AST and ALT levels at baseline may help predict oxygen requirement in hemodialysis patients with COVID-19.

DOI： 10.2169/internalmedicine.2115-23

Long-term peritoneal dialysate exposure modulates expression of membrane complement regulators in human peritoneal mesothelial cells Reviewed Open Access

Kobayashi, K; Ozeki, T; Kim, H; Imai, M; Kojima, H; Iguchi, D; Fukui, S; Suzuki, M; Suzuki, Y; Maruyama, S; Ito, Y; Mizuno, M

Front Med Vol. 9 page： 972592 2022.12

Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS) Reviewed Open Access

Kimura, T; Yamamoto, R; Yoshino, M; Sakate, R; Imai, E; Maruyama, S; Yokoyama, H; Sugiyama, H; Nitta, K; Tsukamoto, T; Uchida, S; Takeda, A; Sato, T; Wada, T; Hayashi, H; Akai, Y; Fukunaga, M; Tsuruya, K; Masutani, K; Konta, T; Shoji, T; Hiramatsu, T; Goto, S; Tamai, H; Nishio, S; Nagai, K; Yamagata, K; Yasuda, H; Ichida, S; Naruse, T; Nishino, T; Sobajima, H; Akahori, T; Ito, T; Terada, Y; Katafuchi, R; Fujimoto, S; Okada, H; Mimura, T; Suzuki, S; Saka, Y; Sofue, T; Kitagawa, K; Fujita, Y; Mizutani, M; Kashihara, N; Sato, H; Narita, I; Isaka, Y

Clin Exp Nephrol Vol. 26 ( 12 ) page： 1170 - 1179 2022.12

Predicting oxygen requirements in patients with coronavirus disease 2019 using an artificial intelligence-clinician model based on local non-image data Reviewed Open Access

Muto, R; Fukuta, S; Watanabe, T; Shindo, Y; Kanemitsu, Y; Kajikawa, S; Yonezawa, T; Inoue, T; Ichihashi, T; Shiratori, Y; Maruyama, S

Front Med Vol. 9 page： 1042067 2022.11

Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis Reviewed Open Access

Kitai, H; Kato, N; Ogami, K; Komatsu, S; Watanabe, Y; Yoshino, S; Koshi, E; Tsubota, S; Funahashi, Y; Maeda, T; Furuhashi, K; Ishimoto, T; Kosugi, T; Maruyama, S; Kadomatsu, K; Suzuki, HI

BMC Biol Vol. 20 ( 1 ) page： 248 2022.11

Influence of COVID-19 on the 10-year carbon footprint of the Nagoya University Hospital and medical research centre Reviewed Open Access

Morooka, H; Yamamoto, T; Tanaka, A; Furuhashi, K; Miyagawa, Y; Maruyama, S

Global Health Vol. 18 ( 1 ) page： 92 2022.11

Identifying high-risk population of depression: association between metabolic syndrome and depression using a health checkup and claims database Reviewed Open Access

Imaizumi, T; Toda, T; Maekawa, M; Sakurai, D; Hagiwara, Y; Yoshida, Y; Ando, M; Maruyama, S

Sci Rep Vol. 12 ( 1 ) page： 18577 2022.11

Impact of Urinary Protein Examination on Early Diagnosis of CKD: A Nationwide Hospital-Based Observational Study in Japan, REAL-CKD

Maruyama, S; Tanaka, T; Takeda, M; Morita, N; Yajima, T

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY Vol. 33 ( 11 ) page： 301 - 301 2022.11

Acute Kidney Injury and Remission of Proteinuria in Minimal Change Disease. Reviewed Open Access

Yamamoto, R; Imai, E; Maruyama, S; Yokoyama, H; Sugiyama, H; Takeda, A; Uchida, S; Tsukamoto, T; Tsuruya, K; Akai, Y; Nitta, K; Fukunaga, M; Hayashi, H; Shoji, T; Masutani, K; Konta, T; Katafuchi, R; Nishio, S; Wada, T; Goto, S; Tamai, H; Shirasaki, A; Nagai, K; Nishino, T; Yamagata, K; Kazama, JJ; Hiromura, K; Yasuda, H; Sofue, T; Fujimoto, S; Mizutani, M; Naruse, T; Hiramatsu, T; Morozumi, K; Sobajima, H; Saka, Y; Ishimura, E; Ito, T; Ichikawa, D; Shigematsu, T; Sato, H; Narita, I; Yoshitaka, I

Kidney Int Rep Vol. 7 ( 10 ) page： 2283 - 2288 2022.10

A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan Reviewed

Ikeuchi, H; Sugiyama, H; Sato, H; Yokoyama, H; Maruyama, S; Mukoyama, M; Hayashi, H; Tsukamoto, T; Fukuda, M; Yamagata, K; Ishikawa, E; Uchida, K; Kamijo, Y; Nakagawa, N; Tsuruya, K; Nojima, Y; Hiromura, K

Actions Vol. 26 ( 9 ) page： 898 - 908 2022.9

　 PREV - NEXT 　

<MARUYAMA, Shoichi>

Papers - MARUYAMA, Shoichi